THERAPY TREATMENTS OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM

可手术直肠癌患者的治疗

• 批准号: 7376330
• 负责人: WILLIAM MCKINNON
• 金额: $ 0.16万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376330
• 关键词: THERAPY; TREATMENTS; PATIENTS; OPERABLE; CARCINOMA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this study is to compare the rate of local-regional relapse in patients receiving preoperative oral capecitabine with radiotherapy (XRT) to that in patients receiving preoperative continuous intravenous infusion (CVI) 5-FU capecitabine with radiotherapy (XRT) to that in patients receiving preoperative continuous intravenous infusion (CVI) 5-FU + XRT. The secondary aims are to: 1) downstage the primary tumor, 2) increase the number of patients undergoing sphincter-saying surgery, 3) correlate genetic patterns and the presence of absence of specific tissue biomarkers with response and prognosis, 4) compare oral capecitabine and CVI 5-FU on QOL in the setting of preoperative RT for rectal cancer, 5) examine the differences in toxicity and burden of care for the two CT treatment regimens and 6) describe the impact of the type of surgical management of rectal cancer on QOL at 1 year after surgical treatment. The tertiary aim is to establish an annotated tissue library with samples being obtained prior to therapy and following therapy, prior to surgery.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的主要目的是比较接受术前口服卡培他滨联合放疗（XRT）的患者与接受术前连续静脉输注（CVI）5-FU卡培他滨联合放疗（XRT）的患者的局部区域复发率。接受术前连续静脉输注（CVI）5-FU + XRT的患者。次要目标是：1）降低原发性肿瘤的分期，2）增加接受括约肌切除术的患者数量，3）将遗传模式和是否存在特定组织生物标志物与反应和预后相关，4）在直肠癌术前RT的背景下比较口服卡培他滨和CVI 5-FU对QOL的影响，5）检查两种CT治疗方案的毒性和护理负担的差异，6）描述直肠癌手术治疗类型对手术治疗后1年生活质量的影响。第三个目标是建立一个注释的组织库，其中在治疗前和治疗后，手术前获得样本。